Cargando…
A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope(®)) During a Phase III Clinical Trial
INTRODUCTION: An initial Phase III clinical trial has evaluated the efficacy and safety of biosimilar recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz) in Spanish children with growth hormone deficiency (GHD). At the end of the study, those patients still growing were offered to remain o...
Autores principales: | Borrás Pérez, Victoria, López-Siguero, Juan Pedro, Martínez, Gabriela, Corripio, Raquel, Fernández, Juan Manuel, Labarta, Jose Ignacio, Ferrer, Marta, Cabrinety, Nuria, Prieto, Pablo, Ramón-Krauel, Marta, Bosch, Jordi, Espino, Rafael, Palla Garcia, Margarida, Rebollo, Francisco Jose |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349959/ https://www.ncbi.nlm.nih.gov/pubmed/25667132 http://dx.doi.org/10.1007/s12325-015-0181-9 |
Ejemplares similares
-
Isolated Growth Hormone Deficiency and Idiopathic Short Stature: Comparative Efficiency after Growth Hormone Treatment up to Adult Height
por: Ariza-Jimenez, Ana-Belen, et al.
Publicado: (2021) -
Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020) -
Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
por: Iughetti, Lorenzo, et al.
Publicado: (2016) -
Ten years’ clinical experience with biosimilar human growth hormone: a review of efficacy data
por: López-Siguero, Juan Pedro, et al.
Publicado: (2017) -
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)